3 documents found, page 1 of 1
A Portuguese expert panel position paper on the management of heart failure wit...
Silva-Cardoso, José; Moreira, Emília; Melo, Rachel Tavares de; Moraes-Sarmento, Pedro; Cardim, Nuno; Oliveira, Mário; Gavina, Cristina; Moura, BrendaIn Portugal, a 15.2% prevalence of heart failure with preserved ejection fraction (HFpEF) was recently identified among those aged ≥50 years. HFpEF represents 90% of Portuguese heart failure patients. HFpEF management in Portugal is challenging due to patient heterogeneity, diagnostic and therapeutic complexity, and organizational constraints on the healthcare system. Considering the above, a panel of Portugues...
A Portuguese expert panel position paper on the management of heart failure wit...
Silva-Cardoso, José; Moreira, Emília; Melo, Rachel Tavares de; Moraes-Sarmento, Pedro; Cardim, Nuno; Oliveira, Mário; Gavina, Cristina; Moura, BrendaHeart failure (HF) with preserved ejection fraction (HFpEF) affects more than 50% of HF patients worldwide, and more than 70% of HF patients aged over 65. This is a complex syndrome with a clinically heterogeneous presentation and a multifactorial pathophysiology, both of which make its diagnosis and treatment challenging. A Portuguese HF expert panel convened to address HFpEF pathophysiology and therapy, as we...
Sodium-glucose co-transporter 2 inhibitors in the failing heart : a growing pot...
Brito, Dulce; Bettencourt, Paulo; Carvalho, Davide; Ferreira, Jorge; Fontes-Carvalho, Ricardo; Franco, Fátima; Moura, Brenda; Silva-Cardoso, José CarlosSodium-glucose co-transporter 2 inhibitors (SGLT2i) are a new drug class designed to treat patients with type 2 diabetes (T2D). However, cardiovascular outcome trials showed that SGLT2i also offer protection against heart failure (HF)–related events and cardiovascular mortality. These benefits appear to be independent of glycaemic control and have recently been demonstrated in the HF population with reduced eje...